Content

Welcome to the CJU website » LOG IN

Details

BCG pyelonephritis following intravesical therapy for transitional cell carcinoma
Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida, USA
Apr 2007 (Vol. 14, Issue 2, Pages( 3523 - 3525)
PMID: 17466161

Abstract

Text-Size + 

  • Bacillus Calmette-Guerin (BCG) is a common intravesical agent utilized for superficial transitional cell carcinoma of the bladder. The potential for side effects and complications does exist secondary to the utilization of live attenuated bacteria. We present the case of a 70-year old male that developed BCG pyelonephritis and associated renal mass following the fifth of six weekly intravesical BCG therapies. The patient improved clinically and renal mass resolved following 3 months of isoniazid monotherapy without renal biopsy.

Current Issue

October 2017, Vol.24 No.5
canadian journal of urology mobile

canadian journal of urology